Evidence map›Paper›PMID 39630689›Full record

ArticlePloS one2024

TRIO RVEMVS: A Bayesian framework for rare variant association analysis with expectation-maximization variable selection using family trio data.

Duo Yu, Matthew Koslovsky, Margaret C Steiner, Kusha Mohammadi, Chenguang Zhang, Michael D Swartz

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Duo YuDivision of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America.ORCID 0000-0002-8988-1646
Matthew KoslovskyDepartment of Statistics, Colorado State University, Fort Collins, Colorado, United States of America.
Margaret C SteinerDepartment of Human Genetics, University of Chicago, Chicago, Illinois, United States of America.
Kusha MohammadiDepartment of Biostatistics and Data Management, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America.
Chenguang ZhangBiostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, Pennsylvania, United States of America.
Michael D SwartzDepartment of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, United States of America.ORCID 0000-0003-3953-8775

Funding

A Novel Trio-based Bayesian Method to Identify Rare Variants for Birth DefectsR03HD083674 · NICHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI SWARTZ, MICHAEL D · 2016 to 2017
$154k
NICHD NIH HHS R03 HD083674
6 · The paper itself

Abstract

It is commonly reported that rare variants may be more functionally related to complex diseases than common variants. However, individual rare variant association tests remain challenging due to low minor allele frequency in the available samples. This paper proposes an expectation maximization variable selection (EMVS) method to simultaneously detect common and rare variants at the individual variant level using family trio data. TRIO_RVEMVS was assessed in both large (1500 families) and small (350 families) datasets based on simulation. The performance of TRIO_RVEMVS was compared with gene-level kernel and burden association tests that use pedigree data (PedGene) and rare-variant extensions of the transmission disequilibrium test (RV-TDT). At the region level, TRIO_RVEMVS outperformed PedGene and RV-TDT when common variants were included. TRIO_RVEMVS performed competitively with PedGene and outperformed RV-TDT when the analysis was only restricted to rare variants. At the individual variants level, with 1,500 trios, the average true positive rate of individual rare variants that were polymorphic across 500 datasets was 12.20%, and the average false positive rate was 0.74%. In the datasets with 350 trios, the average true and false positive rates of individual rare variants were 13.10% and 1.30%, respectively. When applying TRIO_RVEMVS to real data from the Gabriella Miller Kids First Pediatric Research Program, it identified 3 rare variants in q24.21 and q24.22 associated with the risk of orofacial clefts in the Kids First European population.

Indexed as

Bayes TheoremComputer SimulationGene FrequencyGenetic Predisposition to DiseaseGenetic VariationHumansLinkage DisequilibriumModels, GeneticPedigreePolymorphism, Single Nucleotide

Identifiers

PMID39630689
PMCPMC11616829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.